Atossa Therapeutics CEO Dr Steven Quay joined Steve Darling from Proactive to share news the company has been granted, by the U.S. Patent office, a new patent directed to enterically encapsulated Endoxifen compositions formulated as a suspension. These will include all liquid suspension formulations suitable for oral administration and dispersible tablets, powders, granules, pellets, or sprinkles for reconstitution. Endoxifen is now protected by three issued U.S. patents and numerous pending patents.
Dr. Quay emphasizes the importance of intellectual property and ongoing patent activities to protect the company's innovations and facilitate potential partnerships with larger pharmaceutical companies. Quay telling Proactive this is an important patent as the company learn more about the potential therapeutic role of Endoxifen beyond breast cancer and mammographic breast density. The company also shares more details about suspension formulation and when and how it can be used.